"studyAcronym","id","studyTitle","uuid:ID","studyVersion","studyRationale"
"H2Q-MC-LZZT","StudyVersion_1","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","b50556a9-2cb7-4b9c-aaa8-a8f17320713d","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
